Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I haven't had a home rub in a while. They're charging more these days...
Please provide some evidence, a link will do, that the market believes Ken is a con man. Thanks in advance.
Thanks
Ziopharm came out with a PR regarding their SP decline. Time for a PR from Ken?
New job openings:
Director, Human Resources
Overview
Direct the organization’s recruitment and employment function; Establish employment policies and communicate policy, procedure and regulation to hiring management staff; Oversee team member onboarding process; Direct the development, management and maintenance of job descriptions to ensure that the elements achieve expected results; Oversee the administration of Family & Medical Leave, Worker’s compensation, etc.;
Sr. Scientist
Overview
Candidate will be responsible for the for development, execution, interpretation, and trouble-shooting of molecular biology and microbiology-based laboratory work and experiments in support of advancing our Listeria based immunotherapies. Candidate should be prepared to develop and follow established protocols, identify and incorporate improved methods, analyze data, and keep meticulous notes. Candidate should be able to bring new methodologies to the lab and be able to train/manage others.
You should pay more attention to what you read. I have never owned warrants but hey, thanks for playing!
You don't know how to read a chart.
If you could read a chart, you'd see buying at the open was the biggest volume. Nice try, though.
Looks like a new position.
Post any NEO vaccine that has FDA approval & is on the market. LOL
A strong first deal for HOT should set a precedent. I forget who posted this but someone alluded to selling off all of HOT to one company was prohibitively expensive for the acquirer. So, I expect multiple deals. It just takes one to start the ball rolling.
The SP goes up (one deal we may see $5 - $10, just an uneducated guess) and I go the Cape Cod.
Keithz, I'm not sweating it, just tired of the same arguments with no facts to back them up. I asked someone who supposedly has a bio background to explain to me why the science was flawed. Still waiting...
Any trial can have a clinical hold. On the hold before last, Advaxis was exonerated. I didn't see the FDA point the finger at the company this time, either. The raise had to be done. I find Ken fairly credible. Perhaps, you can point out to me why I'm wrong in my assumption.
I think we know who the scammer is.
"In discussions...", I REALLY like that part!
I'm sure there are many who would now take $5 and be happy with it. Why not? If you bought at the lows, you'd make a handsome profit. I prefer to think that Advaxis has the potential to hit $20. A lot is riding on HOT and NEO. The Lm platform works and, I believe, that NEO and HOT will demonstrate increased efficacy. The company must believe in the preclinical data to move forward and as NEO has entered clinical trials, its effect should be seen in matter of months or they'll have a least a glimmer of its performance. We'll know soon enough.
Husker, I am in total agreement with your assessment. I think NEO & HOT will improve the already impressive efficacy of the Lm platform. As for the "Just the ramblings from a drunk redneck...", have you ever heard the ramblings of a drunk Irish/Italian? I can ramble with the best. We'll ramble at Batermere's sushi party!
I think it's safe to say the Lm platform is efficacious. Now, it's being fortified (for lack of a better word) to promote a stronger immune response. BP, I think, has to be interested. Amgen would be the obvious choice for a bigger, better partnership but I wouldn't rule out Merck. It's just a matter of time.
And, it's had very good success in canines.
You're right it will not be fast however, early signs of efficacy may induce BP to start making smart deals with us.
For some, I think the jury is still out on Ken as CEO. I see a CEO who is making better calls then his predecessors to ensure cash conservation and moving bigger market (hopefully) items to the front of the line. “With our announcement today of plans for a second IND submission for an ADXS-HOT construct in prostate cancer, we feel confident we can reach proof-of-concept for these off-the-shelf therapeutics in a relatively rapid and cost-effective manner.” I like that statement. We'll know soon enough how effective Ken is. If he can nail a couple of good, up-front cash deals, my hat will be off to him.
A CC would have been an excellent idea.
Can any chart people tell me why, if I'm looking at bigger spikes of green than red on the Yahoo daily chart, we are not rising instead of sinking?
Wouldn't they have to have pre-clinical data before filing an IND?
Did someone have an inkling the EMA wanted more info? I would not be surprised.
Well, you stay around here so you must have some interest.
Well, then it makes sense that any naysayers sell now (if they indeed hold shares) and cut their losses. To do anything else would be insanity, if they really feel that way.
hindsight might suggest ADXS was overly ambitious and spread themselves very thin with too many non or under funded initiatives they’ve now suspended.
I would like to see lung cancer as the next HOT indication due to the high date rate though I feel, if a deal can be worked out with Merck, it may be prostate.
A deal for HOT. NSCLC and prostate are sizeable markets. I had hoped to see a deal announced concurrent with the IND but, hopefully, we'll see some interest in partnering. I've put as much as I can here. If I see a turnaround soon, I may add more. Looking at the bar chart on Yahoo, it looks like ribbon Christmas candy. Red, green, red, green. Appears to be a decent amount of green there. Ken was smart to announce the filing of the IND for HOT at the same time of the EMA announcement.
Excellent! Now, please be so kind us to educate why Advaxis' science will fail. Thanks in advance.
That is my thought also but I'm trying not to get my hopes up too much. I think a deal for AXAL and PSA would push us up even higher. Oh, and then there's that pesky hold.
There's always a chance a trial will not go well but, if this was one of those, I would think they would have stopped the trial to cut their losses. There has been no update of enrollment (as far as I know) and they have 117 sites open so I am guessing there haven't been any snafus. I would like to hear an update on enrollment, though.
I think a strong deal with the announcement of the HOT IND (and that, I hope, is the reason for the delay) could get us to $5, which would be a good start.
According to this link, yes. However, Advaxis has not always been on top of keeping these pages updated (or the corporate presentation since Noelle left).
https://clinicaltrials.gov/ct2/show/NCT02853604?term=ADXS11-001&rank=5
Over two hours now and not even 100k shares traded.